Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexandre Sepriano

Showing results (81-90 of 121) with videos related to

Pageof 13
Sort By:
RMD Open|September 30, 2024
Change in different classes of chronic back pain suspicious of axial spondyloarthritis: a latent transition analysis of the SPACE cohortPhilipp Bosch, Alexandre Sepriano, Mary-Lucy Marques, et al.
Clinical and Experimental Rheumatology|December 7, 2021
Muscle dysfunction in axial spondylarthritis: the MyoSpA studyAgna Neto, Rita Pinheiro Torres, Sofia Ramiro, et al.
Journal of Bone and Mineral Metabolism|August 14, 2012
Smoking is a predictor of worse trabecular mechanical performance in hip fragility fracture patientsAna Maria Rodrigues, Joana Caetano-Lopes, Ana Catarina Vale, et al.
Arthritis Research & Therapy|August 23, 2020
Effectiveness of switching between TNF inhibitors in patients with axial spondyloarthritis: is the reason to switch relevant?Santiago Rodrigues Manica, Alexandre Sepriano, Fernando Pimentel-Santos, et al.
ARP Rheumatology|July 8, 2023
Effectiveness of biosimilar infliximab CT-P13 compared to originator infliximab in biological-naïve patients with rheumatoid arthritis and axial spondyloarthritis: data from the Portuguese RegisterJosé Marona, Alexandre Sepriano, Sofia Ramiro, et al.
Annals of the Rheumatic Diseases|November 14, 2022
Safety of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritisAlexandre Sepriano, Andreas Kerschbaumer, Sytske Anne Bergstra, et al.
RMD Open|February 6, 2016
Prevalence of rheumatic and musculoskeletal diseases and their impact on health-related quality of life, physical function and mental health in Portugal: results from EpiReumaPt- a national health surveyJaime C Branco, Ana M Rodrigues, Nélia Gouveia, et al.
Annals of the Rheumatic Diseases|November 11, 2022
Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritisAndreas Kerschbaumer, Alexandre Sepriano, Sytske Anne Bergstra, et al.
Annals of the Rheumatic Diseases|November 21, 2022
Efficacy, duration of use and safety of glucocorticoids: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritisSytske Anne Bergstra, Alexandre Sepriano, Andreas Kerschbaumer, et al.
RMD Open|March 8, 2020
Eligibility criteria for biologic disease-modifying antirheumatic drugs in axial spondyloarthritis: going beyond BASDAIJose Marona, Alexandre Sepriano, Santiago Rodrigues-Manica, et al.
Pageof 13

Showing results (81-90 of 121) with videos related to

Sort By:
Pageof 13
RMD Open|September 30, 2024
Change in different classes of chronic back pain suspicious of axial spondyloarthritis: a latent transition analysis of the SPACE cohortPhilipp Bosch, Alexandre Sepriano, Mary-Lucy Marques, et al.
Clinical and Experimental Rheumatology|December 7, 2021
Muscle dysfunction in axial spondylarthritis: the MyoSpA studyAgna Neto, Rita Pinheiro Torres, Sofia Ramiro, et al.
Journal of Bone and Mineral Metabolism|August 14, 2012
Smoking is a predictor of worse trabecular mechanical performance in hip fragility fracture patientsAna Maria Rodrigues, Joana Caetano-Lopes, Ana Catarina Vale, et al.
Arthritis Research & Therapy|August 23, 2020
Effectiveness of switching between TNF inhibitors in patients with axial spondyloarthritis: is the reason to switch relevant?Santiago Rodrigues Manica, Alexandre Sepriano, Fernando Pimentel-Santos, et al.
ARP Rheumatology|July 8, 2023
Effectiveness of biosimilar infliximab CT-P13 compared to originator infliximab in biological-naïve patients with rheumatoid arthritis and axial spondyloarthritis: data from the Portuguese RegisterJosé Marona, Alexandre Sepriano, Sofia Ramiro, et al.
Annals of the Rheumatic Diseases|November 14, 2022
Safety of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritisAlexandre Sepriano, Andreas Kerschbaumer, Sytske Anne Bergstra, et al.
RMD Open|February 6, 2016
Prevalence of rheumatic and musculoskeletal diseases and their impact on health-related quality of life, physical function and mental health in Portugal: results from EpiReumaPt- a national health surveyJaime C Branco, Ana M Rodrigues, Nélia Gouveia, et al.
Annals of the Rheumatic Diseases|November 11, 2022
Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritisAndreas Kerschbaumer, Alexandre Sepriano, Sytske Anne Bergstra, et al.
Annals of the Rheumatic Diseases|November 21, 2022
Efficacy, duration of use and safety of glucocorticoids: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritisSytske Anne Bergstra, Alexandre Sepriano, Andreas Kerschbaumer, et al.
RMD Open|March 8, 2020
Eligibility criteria for biologic disease-modifying antirheumatic drugs in axial spondyloarthritis: going beyond BASDAIJose Marona, Alexandre Sepriano, Santiago Rodrigues-Manica, et al.
Pageof 13